Cognito Therapeutics Raises $73M Series B to Advance …

Cambridge, MA, March 22, 2023 (Business Wire) -- Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today a …

CouponFollow Extension

$73
OFF

Cognito Therapeutics Raises $73M Series B To Advance …

6 days from now

Cambridge, MA, March 22, 2023 (Business Wire) -- Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today a …

jacobsmgt.com

$73
OFF

Cognito Therapeutics Raises $73M For Non-invasive Neuromod Tech

6 days from now

Mar 22, 2023 · Cognito Therapeutics announced today that it raised $73 million in a Series B financing round to support its neuromodulation technology. Cambridge, Massachusetts–based …

massdevice.com

$73
OFF

Neurotechnology Company Cognito Therapeutics Scores $73M

6 days from now

March 23, 2023. 09:52 am. Photo courtesy of Cognito Therapeutics. Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative disorders, scored $73 …

mobihealthnews.com

$73
OFF

Cognito Therapeutics Raises $73M In Series B Funding For …

6 days from now

Mar 23, 2023 · Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, has completed a $73M Series B financing round led by …

mpo-mag.com

$73
OFF

Cognito Therapeutics Raises $73M Series B To Advance

6 days from now

Mar 22, 2023 · Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today a $73M Series B financing round led by …

financialcontent.com

$73
OFF

Firm Advises Cognito Therapeutics On $73 Million Series B Financing

6 days from now

Mar 31, 2023 · On March 22, 2023, neurotechnology company Cognito Therapeutics announced a $73 million Series B financing round. The financing was led by FoundersX Ventures with …

wsgr.com

$73
OFF

Cognito Therapeutics Scores $73m Series B - Venture Capital Journal

6 days from now

Mar 22, 2023 · The funding will advance Cognito’s study of its non-invasive neuromodulation device. Cambridge, Massachusetts-based Cognito Therapeutics, a neurotechnology company …

venturecapitaljournal.com

$73
OFF

Series B - Cognito Therapeutics - 2023-03-22 - Crunchbase

6 days from now

Mar 22, 2023 · Built In Boston — Cognito Raises $73M to Combat Alzheimer’s Disease. News • Mar 22, 2023. Business Wire — Cognito Therapeutics Raises $73M Series B to Advance …

crunchbase.com

$73
OFF

Cognito Therapeutics Raises $73M To Advance Study On

6 days from now

Mar 23, 2023 · The company is currently recruiting people to participate in a non-invasive wearable device study that delivers sensory stimulation, and has the potential to slow the …

vator.tv

$73
OFF

Cognito Therapeutics Raises $73M Series B To Advance ... - YouTube

6 days from now

Mar 22, 2023 · MORE INFORMATION:Watch to learn how Cognito's proprietary precision neuromodulation treatment workshttps://www.businesswire.com/news/home/20230322005004/en

youtube.com

$73
OFF

Cognito Therapeutics Raises $73M Series B To Advance ... - BioSpace

6 days from now

Mar 22, 2023 · Cognito Therapeutics announced today a $73M Series B financing round led by FoundersX Ventures with participation from all existing investors. Cognito Therapeutics Raises …

biospace.com

$73
OFF

Cognito Therapeutics Raises $73M Series B To Advance …

6 days from now

The Series B funding brings the total amount raised since inception to $93 million. In addition to the financing, Dr. Rick Kuntz, MD, MSc, former Senior Vice President, Chief Medical and …

vcaonline.com

$35
OFF

Cognito Therapeutics Raises $35M Series B Extension - VatorNews

6 days from now

The round is an extension of the Series B round the company raised $73 million in March 2023 from FoundersX, Morningside, Alzheimer’s Drug Discovery Foundation, IAG Capital, ...

vator.tv

$73
OFF

Cognito Therapeutics Raises $73M Series B To Advance …

6 days from now

Mar 22, 2023 · Cognito Therapeutics Raises $73M Series B To Advance Neurotechnology Platform For Alzheimer’S Disease. Mar 22, 2023 12:14 UTC. COGNITO THERAPEUTICS …

tradingview.com

$73
OFF

Cognito Therapeutics Raises $73M Series B To Advance …

6 days from now

Mar 22, 2023 · Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer’s Disease. Skip to main content. 45° ...

ricentral.com

FAQs about Cognito Therapeutics Raises $73M Series B to Advance … Coupon?

Does Cognito therapeutics have a series B financing?

CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today a $73M Series B financing round led by FoundersX Ventures with participation from all existing investors. ...

Who is Cognito Therapeutics?

About Cognito Therapeutics Cognito Therapeutics is a clinical-stage neurotechnology company developing disease-modifying therapeutic approaches to treat neurodegenerative disorders. Its non-invasive neuromodulation platform was developed by MIT Professors and scientific founders Li-Huei Tsai and Ed Boyden. ...

Where is Cognito based?

The Company’s lead therapy is currently in a pivotal study in Alzheimer’s Disease and was awarded FDA Breakthrough Device Designation. Cognito is based in Cambridge, MA. For more information, visit www.cognitotx.com. Follow us on Twitter at @cognitotx. ...

Is Cognito a non-invasive neuromodulation device?

Its non-invasive neuromodulation platform was developed by MIT Professors and scientific founders Li-Huei Tsai and Ed Boyden. The Company’s lead therapy is currently in a pivotal study in Alzheimer’s Disease and was awarded FDA Breakthrough Device Designation. Cognito is based in Cambridge, MA. ...

Who will join Cognito's Board of directors?

In addition to the financing, Dr. Rick Kuntz, MD, MSc, former Senior Vice President, Chief Medical and Scientific Officer of Medtronic and Helen Liang, Founder & Managing Partner at FoundersX, will join Cognito’s Board of Directors. Dr. ...

Can Cognito change disease processes?

“By broadening the therapeutic target from specific proteins to the underlying neuronal pathophysiology, Cognito’s proprietary approach has shown that it can fundamentally alter disease processes and potentially achieve disease modification unique from more traditional approaches. ...